NEW YORK, March 18, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Mallinckrodt plc (NYSE: MNK), Novo Nordisk A/S (NYSE: NVO), Charles River Laboratories International, Inc. (NYSE: CRL), Cerner Corporation (NASDAQ: CERN), and Quintiles Transnational Holdings Inc. (NYSE: Q). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Mallinckrodt plc Analyst Notes
On March 12, 2014, Mallinckrodt plc (Mallinckrodt) announced the U.S. Food and Drug Administration's (FDA) approval of XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), formerly known as MNK-795, for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options are ineffective. According to Mallinckrodt, the approval is partly based on the pivotal Phase 3 efficacy study conducted in an acute post-surgical pain model. The Company stated that XARTEMIS XR met the study's primary endpoint and showed statistically significant improvement in pain scores compared to placebo from baseline over 48 hours. Commenting on the approval, Mark Trudeau, President and CEO of Mallinckrodt, stated, "The FDA approval of XARTEMIS XR exemplifies Mallinckrodt's dedication to developing and providing new treatment options for people with pain. Mallinckrodt remains committed to continuing its work to develop innovative formulations for our product lines to help ensure access to appropriate pain treatment for the millions of patients suffering from acute pain, and we will continue to work closely with the FDA as we engage in further development programs for XARTEMIS XR and other products utilizing this technology platform." The full analyst notes on Mallinckrodt plc are available to download free of charge at:
http://www.AnalystsReview.com/03182014/MNK/report.pdf
Novo Nordisk A/S Analyst Notes
On March 12, 2014, Novo Nordisk A/S' (Novo Nordisk) stock declined 1.03%, closing at $46.02. For the past three-day trading period, the Company's stock went down by 2.91%, compared to the Dow Jones Industrial Average which lost 0.68% during the same three-day trading period. The full analyst notes on Novo Nordisk A/S are available to download free of charge at:
http://www.AnalystsReview.com/03182014/NVO/report.pdf
Charles River Laboratories International, Inc. Analyst Notes
On March 13, 2014, Charles River Laboratories International, Inc. (Charles River Laboratories) announced that it has entered into a definitive agreement to acquire the contract research organization (CRO) services division of Galapagos NV, including both Argenta and BioFocus for a purchase price of €129 million in cash or c. $179 million. According to Charles River Laboratories, the acquisition will position the Company as a full service, early-stage CRO, with integrated in vitro and in vivo capabilities from target discovery through preclinical development. Additionally, the Company stated that along with the initial purchase price, the transaction also includes future performance payments of up to €5 million or c. $7 million. Commenting on the release, James C. Foster, Chairman, President and CEO of Charles River Laboratories stated, "We believe that this acquisition expands our unique drug discovery and early-stage development focus and advances Charles River's position as a market leader in the fast-growing outsourced discovery services market." He concluded, "The acquisition will enhance our sales growth rate and be accretive to non-GAAP earnings per share in 2014, and we expect increased contribution in 2015 and beyond." The full analyst notes on Charles River Laboratories International, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03182014/CRL/report.pdf
Cerner Corporation Analyst Notes
On March 12, 2014, Cerner Corporation's (Cerner) stock declined 0.13%, to close at $59.86. Over the past one-month trading period, Cerner shares increased by 3.29%, compared to the Nasdaq Composite which went up by 2.89% during the same trading session. The full analyst notes on Cerner Corporation are available to download free of charge at:
http://www.AnalystsReview.com/03182014/CERN/report.pdf
Quintiles Transnational Holdings Inc. Analyst Notes
On March 12, 2014, Quintiles Transnational Holdings Inc. (Quintiles) reported that for the third time, the Company has been named as the "Best CRO in Asia" at the 2014 BioPharma Asia Industry Awards dinner. According to the Company, the award recognizes the contract research organization that has best demonstrated an ongoing commitment to improve clinical research in Asia and help customers succeed. Ken Lee, M.D., Quintiles Vice President and Regional General Manager for Southeast Asia, who accepted the award, stated, "This award reflects Quintiles' ability to improve our customers' probability of success by combining market knowledge with superior service. For 20 years we've been helping our customers navigate Asia's complex and changing healthcare environment. It's wonderful to be acknowledged for our excellence in bringing knowledge and people together for a healthier world." The full analyst notes on Quintiles Transnational Holdings Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03182014/Q/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsReview.com/
SOURCE Analysts Review
